Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study

被引:7
作者
Gabriel, Daniel [1 ]
Jakubovski, Ewgeni [1 ,3 ]
Taylor, Jerome H. [1 ,2 ]
Artukoglu, Bekir B. [1 ]
Bloch, Michael H. [1 ,2 ]
机构
[1] Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[3] Hannover Med Sch, Dept Psychiat Social Psychiat & Psychotherapy, Hannover, Germany
基金
美国国家卫生研究院;
关键词
Psychotic disorders; Clinical trial; Children; Response; Schizophrenia; Schizoaffective disorder; Pediatric; 1ST-EPISODE SCHIZOPHRENIA; 1ST EPISODE; MEDICATION; INTERVENTION; ADOLESCENTS; SUBGROUPS; REMISSION; ADHERENCE; SYMPTOMS; EFFICACY;
D O I
10.1016/j.psychres.2017.05.038
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) compared the efficacy of risperidone, olanzapine, and molindone over 8 weeks in 119 youths age 8-19 years with early-onset schizophrenia or schizoaffective disorder. From this large dataset, we examined predictors of treatment response and drop out using stepwise regression and receiver operating characteristics curve (ROC) analysis. Treatment response was defined as having both a >= 20% improvement in Positive and Negative Syndrome Scale (PANSS) score and a Clinical Global Impression-Improvement (CGI-I) score < 3. More severe baseline symptoms, having a history of being in an early education program, and previous prescription of a mood stabilizer increased the likelihood of responding to treatment. Anhedonia and poor community functioning predicted a reduction in symptom severity on the PANSS. Random assignment to different antipsychotic treatment was not predictive of outcome. Parental report of aggressive behaviors at baseline and being African American were associated with a greater likelihood of drop out. Our results suggest youth with more severe psychotic symptoms are most likely to benefit from treatment with antipsychotics and that aggressive youth may require additional support to improve treatment adherence. Further investigation is needed to understand potentially modifiable predictors of response like early education programs.
引用
收藏
页码:248 / 255
页数:8
相关论文
共 47 条
  • [1] Disparities in mental health treatment in US racial and ethnic minority groups: Implications for psychiatrists
    Atdjian, S
    Vega, WA
    [J]. PSYCHIATRIC SERVICES, 2005, 56 (12) : 1600 - 1602
  • [2] Baker Henningham H., 2014, INT J EPIDEMIOL, V43, P407
  • [3] Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST)
    Boter, Han
    Peuskens, Joseph
    Libiger, Jan
    Fleischhacker, W. Wolfgang
    Davidson, Michael
    Galderisi, Silvana
    Kahn, Rene S.
    [J]. SCHIZOPHRENIA RESEARCH, 2009, 115 (2-3) : 97 - 103
  • [4] Predictors of acute treatment response in patients with a first episode of non-affective psychosis:: Sociodemographics, premorbid and clinical variables
    Crespo-Facorro, Benedicto
    Pelayo-Teran, Jose Maria
    Perez-Iglesias, Rocio
    Ramirez-Bonilla, MariLuz
    Martinez-Garcia, Obdulia
    Pardo-Garcia, Gema
    Vazquez-Barquero, Jose Luis
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2007, 41 (08) : 659 - 666
  • [5] Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study
    Crespo-Facorro, Benedicto
    Ortiz-Garcia de la Foz, Victor
    Ayesa-Arriola, Rosa
    Perez-Iglesias, Rocio
    Mata, Ignacio
    Suarez-Pinilla, Paula
    Tabares-Seisdedos, Rafael
    Luis Vazquez-Barquero, Jose
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2013, 44 : 162 - 167
  • [6] Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial
    Czobor, Pal
    Volavka, Jan
    Derks, Eske M.
    Bitter, Istvan
    Libiger, Jan
    Kahn, Rene S.
    Fleischhacker, W. Wolfgang
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (02) : 258 - 261
  • [7] DAVIS JM, 1993, J CLIN PSYCHIAT, V54, P24
  • [8] Findling RL, 2010, J AM ACAD CHILD ADOL, V49
  • [9] Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia
    Findling, Robert L.
    Landbloom, Ronald P.
    Mackle, Mary
    Pallozzi, Wendi
    Braat, Sabine
    Hundt, Carla
    Wamboldt, Marianne Z.
    Mathews, Maju
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2015, 25 (05) : 384 - 396
  • [10] Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study
    Findling, Robert L.
    Johnson, Jacqueline L.
    McClellan, Jon
    Frazier, Jean A.
    Vitiello, Benedetto
    Hamer, Robert M.
    Lieberman, Jeffrey A.
    Ritz, Louise
    McNamara, Nora K.
    Lingler, Jacqui
    Hlastala, Stefanie
    Pierson, Leslie
    Puglia, Madeline
    Maloney, Ann E.
    Kaufman, Emily Michael
    Noyes, Nancy
    Sikich, Linmarie
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2010, 49 (06) : 583 - 594